UA118094C2 - Заміщені зворотні піримідинові інгібітори bmi-1 - Google Patents

Заміщені зворотні піримідинові інгібітори bmi-1

Info

Publication number
UA118094C2
UA118094C2 UAA201505533A UAA201505533A UA118094C2 UA 118094 C2 UA118094 C2 UA 118094C2 UA A201505533 A UAA201505533 A UA A201505533A UA A201505533 A UAA201505533 A UA A201505533A UA 118094 C2 UA118094 C2 UA 118094C2
Authority
UA
Ukraine
Prior art keywords
bmi
inhibitors
substituted reverse
reverse pyrimidine
inhibit
Prior art date
Application number
UAA201505533A
Other languages
English (en)
Inventor
Чанґ-Сун Лі
Раміл Баязітов
Ліанґксіань Као
Томас Дабл'ю. Девіс
Ву Ду
Ронґґанґ Лю
Янґ-чун Мун
Стівен Ді. Педжет
Хонґю Рен
Надія Сидоренко
Ричард Геральд Вілд
Original Assignee
Пітісі Терап'Ютикс, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пітісі Терап'Ютикс, Інк. filed Critical Пітісі Терап'Ютикс, Інк.
Publication of UA118094C2 publication Critical patent/UA118094C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

У цьому винаході описані амінозаміщені обернені піримідинові сполуки та їх форми, які інгібують функцію та знижують рівень специфічного до В-клітин білка інсерційного сайта 1 вірусу лейкозу мишей Молоні (Вmі-1), та способи їх застосування для інгібування функції Вmі-1 та зниження рівня Вmі-1 для лікування раку, опосередкованого Вmі-1.
UAA201505533A 2012-11-21 2013-11-21 Заміщені зворотні піримідинові інгібітори bmi-1 UA118094C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
PCT/US2013/071132 WO2014081906A2 (en) 2012-11-21 2013-11-21 Substituted reverse pyrimidine bmi-1 inhibitors

Publications (1)

Publication Number Publication Date
UA118094C2 true UA118094C2 (uk) 2018-11-26

Family

ID=50776672

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201505533A UA118094C2 (uk) 2012-11-21 2013-11-21 Заміщені зворотні піримідинові інгібітори bmi-1

Country Status (32)

Country Link
US (3) US10428050B2 (uk)
EP (1) EP2922828B1 (uk)
JP (3) JP6412503B2 (uk)
KR (4) KR102356487B1 (uk)
CN (2) CN111423417B (uk)
AR (1) AR093579A1 (uk)
AU (1) AU2013348009C1 (uk)
BR (1) BR112015011760B1 (uk)
CA (1) CA2892045C (uk)
CL (1) CL2015001377A1 (uk)
CR (1) CR20150294A (uk)
CU (1) CU24387B1 (uk)
DK (1) DK2922828T3 (uk)
EA (2) EA031405B1 (uk)
EC (1) ECSP15019948A (uk)
ES (1) ES2821529T3 (uk)
HK (1) HK1215032A1 (uk)
IL (2) IL238871B (uk)
MA (1) MA38208B1 (uk)
MX (2) MX2015006469A (uk)
NI (1) NI201500072A (uk)
NZ (2) NZ746607A (uk)
PE (1) PE20151413A1 (uk)
PH (1) PH12015501130A1 (uk)
PL (1) PL2922828T3 (uk)
PT (1) PT2922828T (uk)
SA (1) SA517381847B1 (uk)
SG (2) SG10201600149VA (uk)
TW (1) TWI623531B (uk)
UA (1) UA118094C2 (uk)
WO (1) WO2014081906A2 (uk)
ZA (1) ZA201503642B (uk)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014081906A2 (en) 2012-11-21 2014-05-30 Ptc Therapeutics, Inc. Substituted reverse pyrimidine bmi-1 inhibitors
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
EP3019480B1 (en) * 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3039015B1 (en) 2013-08-30 2019-10-30 PTC Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
CN108351862B (zh) 2015-08-11 2023-08-22 科格诺亚公司 利用人工智能和用户输入来确定发育进展的方法和装置
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
EP3402780A1 (en) * 2016-01-14 2018-11-21 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
GB2575740A (en) * 2017-02-09 2020-01-22 Congoa Inc Platform and system for digital personalized medicine
EP3664803A4 (en) 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
CN113164479A (zh) * 2018-08-17 2021-07-23 Ptc医疗公司 用于治疗胰腺癌的方法
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
AU2020209767A1 (en) 2019-01-15 2021-07-29 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia
MX2021010398A (es) * 2019-02-28 2022-01-18 Ptc Therapeutics Inc Metodo para tratar un mieloma multiple.
KR20210151061A (ko) * 2019-03-11 2021-12-13 피티씨 테라퓨틱스, 인크. 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형
WO2020198065A1 (en) 2019-03-22 2020-10-01 Cognoa, Inc. Personalized digital therapy methods and devices
US20220152024A1 (en) * 2019-03-27 2022-05-19 Ptc Therapeutics, Inc. Combinations useful in a method for treating sarcoma
CA3135929A1 (en) * 2019-04-02 2020-10-08 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (uk) 1973-09-20 1977-11-30 Delalande Sa
CN1102144C (zh) 1994-08-13 2003-02-26 株式会社柳韩洋行 新的嘧啶衍生物及其制备方法
IN188411B (uk) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
WO2001030778A1 (en) 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
AU2001242629B2 (en) 2000-03-29 2005-08-11 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
EP1317449B1 (en) 2000-09-15 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6710048B2 (en) 2000-09-20 2004-03-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
ATE300541T1 (de) 2000-12-15 2005-08-15 Glaxo Group Ltd Pyrazolopyridinderivate
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
KR20030076688A (ko) 2001-02-20 2003-09-26 아스트라제네카 아베 Ｇｓｋ3-관련 장애의 치료를 위한 2-아릴아미노-피리미딘
WO2002070662A2 (en) * 2001-03-02 2002-09-12 Gpc Biotech Ag Three hybrid assay system
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
ATE337312T1 (de) 2001-07-03 2006-09-15 Vertex Pharma Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003212634A1 (en) * 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
AU2003229370B2 (en) 2002-05-23 2009-02-26 Ym Biosciences Australia Pty Ltd Kinase inhibitors
EP1533304B1 (en) 2002-06-28 2009-11-04 Nippon Shinyaku Co., Ltd. Amide derivative
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
US7060850B2 (en) * 2002-07-11 2006-06-13 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
EP1551842A1 (en) 2002-10-15 2005-07-13 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
CA2545427C (en) 2004-01-12 2012-08-21 Cytopia Research Pty Ltd Selective kinase inhibitors
US20070117818A1 (en) 2004-02-04 2007-05-24 Masaichi Hasegawa Pyrimidinone compounds useful as kinase inhibitors
MXPA06011327A (es) * 2004-03-30 2006-12-15 Vertex Pharma Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
AU2006219231B2 (en) 2005-02-28 2010-01-14 Japan Tobacco Inc. Novel aminopyridine compound with Syk inhibitory activity
EA200701930A1 (ru) 2005-03-10 2008-02-28 Байер Фармасьютикалс Корпорейшн Производные пиримидина для лечения гиперпролиферативных нарушений
WO2007147874A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
CN101516873A (zh) 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
EP2074113A1 (en) * 2006-10-03 2009-07-01 NeuroSearch A/S Indazolyl derivatives useful as potassium channel modulating agents
MX2009004019A (es) 2006-10-19 2009-06-19 Signal Pharm Llc Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa.
EP2094682A2 (en) 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
WO2008132502A1 (en) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
UA104849C2 (uk) 2007-11-16 2014-03-25 Інсайт Корпорейшн 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
WO2009071701A1 (en) 2007-12-07 2009-06-11 Novartis Ag Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
EP2271631B1 (en) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2306836B1 (en) * 2008-07-01 2016-09-07 PTC Therapeutics, Inc. Bmi-1 protein expression modulators
ATE542813T1 (de) 2008-08-06 2012-02-15 Pfizer 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
US8618099B2 (en) 2008-09-02 2013-12-31 Ataxion, Inc. Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
TW201028399A (en) * 2008-11-27 2010-08-01 Shionogi & Co Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity
CA2755935A1 (en) 2009-02-12 2010-08-19 Astellas Pharma Inc. Hetero ring derivative
KR20110136880A (ko) 2009-03-27 2011-12-21 패스웨이 테라퓨틱스 인코포레이티드 피리미딘일 및 1,3,5-트라이아진일 벤즈이미다졸 설폰아미드 및 암 치료법에서의 이의 용도
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
US20110039873A1 (en) 2009-06-08 2011-02-17 Gaeta Federico C A SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
GEP20156325B (en) * 2009-06-17 2015-07-10 Vertex Pharma Inhibitors of influenza viruses replication
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CN102471345A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡嗪抑制剂
CN102471339A (zh) 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
CA2786800C (en) 2010-01-12 2018-02-27 Ab Science Thiazole and oxazole kinase inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
KR101788903B1 (ko) * 2010-08-19 2017-10-23 에프. 호프만-라 로슈 아게 체세포의 유도된 재프로그래밍된 신경 줄기 세포 (ｉｒｎｓｃｓ) 로의 전환
SG188438A1 (en) 2010-09-13 2013-05-31 Novartis Ag Triazine-oxadiazoles
US20140088056A1 (en) * 2010-09-28 2014-03-27 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
JP2014500277A (ja) * 2010-12-09 2014-01-09 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としての二環式化合物
CN103402997B (zh) 2011-02-25 2015-08-26 柳韩洋行 二氨基嘧啶衍生物及其制备方法
EP2729459B1 (en) * 2011-07-07 2018-08-22 Merck Patent GmbH Substituted azaheterocycles for the treatment of cancer
WO2014081906A2 (en) * 2012-11-21 2014-05-30 Ptc Therapeutics, Inc. Substituted reverse pyrimidine bmi-1 inhibitors
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs

Also Published As

Publication number Publication date
JP6918898B2 (ja) 2021-08-11
BR112015011760B1 (pt) 2022-12-06
PH12015501130A1 (en) 2015-08-03
ZA201503642B (en) 2020-10-28
EP2922828B1 (en) 2020-07-08
KR102455889B1 (ko) 2022-10-17
KR102356487B1 (ko) 2022-02-08
US20200024260A1 (en) 2020-01-23
DK2922828T3 (da) 2020-08-31
EP2922828A2 (en) 2015-09-30
CA2892045C (en) 2022-05-31
SG10201600149VA (en) 2016-02-26
NI201500072A (es) 2016-01-18
MA38208B1 (fr) 2021-12-31
EP2922828A4 (en) 2016-07-27
NZ746607A (en) 2019-11-29
CU20150053A7 (es) 2015-11-27
PT2922828T (pt) 2020-10-12
IL238871A0 (en) 2015-07-30
KR20220143164A (ko) 2022-10-24
AU2013348009A1 (en) 2015-06-04
ES2821529T3 (es) 2021-04-26
IL265253A (en) 2019-05-30
CR20150294A (es) 2015-08-20
EA201590992A1 (ru) 2015-11-30
WO2014081906A3 (en) 2014-07-17
EA035349B1 (ru) 2020-05-29
JP2020055815A (ja) 2020-04-09
HK1215032A1 (zh) 2016-08-12
AU2013348009C1 (en) 2019-08-08
PL2922828T3 (pl) 2020-12-28
KR20220016305A (ko) 2022-02-08
CU24387B1 (es) 2019-03-04
CN104918919A (zh) 2015-09-16
MX2021009892A (es) 2021-09-14
IL238871B (en) 2019-03-31
KR102275676B1 (ko) 2021-07-12
SA517381847B1 (ar) 2021-07-17
KR20210088740A (ko) 2021-07-14
US20150315182A1 (en) 2015-11-05
CL2015001377A1 (es) 2016-02-19
US20220064150A1 (en) 2022-03-03
CN111423417B (zh) 2022-11-15
WO2014081906A2 (en) 2014-05-30
BR112015011760A2 (pt) 2017-07-11
ECSP15019948A (es) 2016-01-29
AU2013348009B2 (en) 2018-05-17
US10428050B2 (en) 2019-10-01
JP2016504290A (ja) 2016-02-12
JP6412503B2 (ja) 2018-10-24
MX2015006469A (es) 2015-10-29
TW201427972A (zh) 2014-07-16
SG11201503982XA (en) 2015-06-29
TWI623531B (zh) 2018-05-11
KR20150086345A (ko) 2015-07-27
US11180483B2 (en) 2021-11-23
CN111423417A (zh) 2020-07-17
CA2892045A1 (en) 2014-05-30
NZ708909A (en) 2019-11-29
JP2019031509A (ja) 2019-02-28
PE20151413A1 (es) 2015-10-23
EA201890142A1 (ru) 2018-06-29
JP6617186B2 (ja) 2019-12-11
AR093579A1 (es) 2015-06-10
EA031405B1 (ru) 2018-12-28

Similar Documents

Publication Publication Date Title
PH12015501130A1 (en) Substituted reverse pyrimidine bmi-1 inhibitors
MX2016002642A (es) Inhibidores de la bmi-1 de pirimidina sustituida.
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
MX2021013118A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
NZ716392A (en) Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX355728B (es) Inhibidores de cinasas.
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
IN2014KN02906A (uk)
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
EA201491013A1 (ru) Пиразиновые ингибиторы киназы
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
MX2018007219A (es) Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
EA201590656A1 (ru) Азаиндолины
PH12018500406A1 (en) Bicyclic compounds as atx inhibitors
PH12018500407A1 (en) New bicyclic compounds as dual atx/ca inhibitors
EA201990239A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы